CAR T-Cell Therapy Market to Surpass Valuation of USD 106.06 Billion by 2031 | SkyQuest Technology [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Westford, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- CAR T-Cell Therapy Market size was valued at USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031). Due to its extraordinary efficacy in combating hematological malignancies such as non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL), the acceptance of CAR T-cell therapy has considerably increased, thereby enhancing the prospects of growth in the industry. CAR T cell therapy is a treatment that concentrates on healthy cells within the body and only attacks the cancerous cells. These benefits are expected to boost growth even further. However, the manufacturing and utilization of CAR T cells was adversely affected due to the advent of the COVID-19 pandemic. Browse in-depth TOC on the " CAR T-Cell Therapy Market" Pages – 197 Tables – 95 Figures – 73 Request your free sample PDF of the report today https://www.skyquestt.com/sample-request/car-t-
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director [Yahoo! Finance]Yahoo! Finance
- Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential' will drive long-term growth [Fortune]Fortune
- BerGenBio Appoints Olav Hellebø as CEO [Yahoo! Finance]Yahoo! Finance
- Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies [Yahoo! Finance]Yahoo! Finance
- NUCLIDIUM Appoints Tony Rosenberg as Chairman of the Board [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/29/24 - Beat
NVS
Sec Filings
- 10/29/24 - Form 6-K
- 10/29/24 - Form 6-K
- 9/18/24 - Form 6-K
- NVS's page on the SEC website